Skip to content
Screener

Alkermes ALKS Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.16B-23.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$100M+4.2%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$106.7M+24.6%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$35M-23.9%
LBR
LB Pharmaceuticals IncLBRX
$7.12M
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$28.6M+63.8%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
TOTAL ASSETS$4,393,125$2,486,993
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses$332,469$289,565
Accrued sales discounts, allowances and reserves295,645247,126
Operating lease liabilities—short-term7,4776,746
Current portion of long-term debt26,500
Total current liabilities662,091543,437

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's accounts payable?
Alkermes (ALKS) reported accounts payable of $332.47M in Q2 2026.
How has Alkermes's accounts payable changed year-over-year?
Alkermes's accounts payable increased by 35.3% year-over-year, from $245.75M to $332.47M.
What is the long-term trend for Alkermes's accounts payable?
Over 5 years (2020 to 2025), Alkermes's accounts payable has grown at a -6.8% compound annual growth rate (CAGR), from $412.17M to $289.57M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Ask your AI about Alkermes's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude